Results 21 to 30 of about 5,988 (201)
The dose-dependent antiangiogenic potential of apixaban: an experimental outlook
Acta Medica Alanya, 2022 Aim: Direct oral anticoagulants (DOACs) are good alternatives to conventional medical regimens for the treatment and prevention of thromboembolism. Apixaban is one of the more popular variations of these newly developed drugs.
Özgür Akkaya, Eyüp Aydoğan
doaj +1 more source
Adverse Events of DOACs in Children
Frontiers in Pediatrics, 2022 Venous thromboembolism (VTE) has an increasing rate of significance in pediatric patients. The currently standardized anticoagulants (unfractionated heparin, low molecular weight heparin and vitamin K antagonists) and their dose regimens were not comprehensively trialed in pediatric patients.
Alessandra Bosch +2 more
openaire +3 more sources
Direct oral anticoagulant: Review article
Journal of Family Medicine and Primary Care, 2022 Venous thromboembolism (VTE) and atrial fibrillation (AF) is a major burden on the health care system. The average occurrence of venous thromboembolism annually is around 108 per 100,000 person-year.
Abdulrahman Nasiri +5 more
doaj +1 more source
Direct oral anticoagulants (DOACs) [PDF]
Vascular Medicine, 2015 DOACs are a new group of blood-thinner medications that may have some advantages over warfarin. A health care provider will look at several different factors to help patients decide if a DOAC is a good choice. Patients taking DOACs should discuss medication changes, a plan for taking the DOAC before and after a surgery, and any bleeding side effects ...
Sara, Vazquez, Matthew T, Rondina
openaire +2 more sources
Рациональная фармакотерапия в кардиологии, 2023 The article is devoted to the discussion of modern approaches to the use of laboratory methods to improve the tactics of using direct oral anticoagulants (DOACs) therapy.
S. R. Gilyarevsky +2 more
doaj +1 more source
Propensity score distribution for warfarin, combined-DOACs, and dabigatran.
, 2022 Note: DOACs = Direct Oral Anticoagulants.
Peter Langhorne (23534) +5 more
core +1 more source
Journal of Pharmaceutical Policy and Practice, 2023 Background Direct oral anticoagulants (DOACs) are considered high-risk medications and used to prevent thromboembolic events and stroke. This study aimed to examine patients’ views and experiences of DOACs use and factors that can promote safety ...
Abdulrhman Al Rowily +6 more
doaj +1 more source
, 2021 Preventing thromboembolic (TE) events “such as stroke” is an important part of managing patients with non-valvular atrial fibrillation (Afib). Over the last 50 years, oral anticoagulant treatment with the Vitamin K Antagonist (VKA) warfarin has played a ...
Szabon, Allen
core +1 more source
An update on laboratory assessment for direct oral anticoagulants (DOACs) [PDF]
, 2019 The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti-Xa inhibitors, have been approved, including rivaroxaban, apixaban ...
Jonathan Douxfils +5 more
core +1 more source
Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)
, 2021 The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous anticoagulant therapies.
Claire Dunois
core +1 more source